<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793620</url>
  </required_header>
  <id_info>
    <org_study_id>V1.1-101</org_study_id>
    <nct_id>NCT04793620</nct_id>
  </id_info>
  <brief_title>Pertussis Acellular Vaccine Adjuvanted With TQL1055</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Active-Controlled Dose-Escalation Study to Assess the Safety and Immunogenicity of Pertussis Acellular Vaccine Adjuvanted With TQL1055 (PAVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adjuvance Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adjuvance Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to evaluate the safety and immunogenicity of the semisynthetic&#xD;
      saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recent increase in the incidence of pertussis has prompted the need for improvements to&#xD;
      current acellular pertussis vaccines. Use of novel adjuvants is one approach to such&#xD;
      improvement. TQL1055 is a rationally designed, semisynthetic analog of the licensed Quillaja&#xD;
      saponin (QS)-21. It has been designed to maintain adjuvant activity with improved&#xD;
      tolerability and greater ease of manufacture.&#xD;
&#xD;
      This is a Phase 1, randomized, double blind, active-controlled sequential-group study,&#xD;
      designed to evaluate the safety, tolerability, and immunogenicity of the combination of&#xD;
      TQL1055 and acellular pertussis vaccine. The dose of TQL1055 will increase by group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Actual">August 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential-group dose-escalation study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>7 days</time_frame>
    <description>Solicited local and systemic adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>365 days</time_frame>
    <description>Adverse Events/Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of abnormal laboratory test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>28 days</time_frame>
    <description>Anti-Pertussis Toxin antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>365 days</time_frame>
    <description>Anti-Pertussis Toxin antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>TQL1055</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQL1055 + acellular pertussis vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acellular pertussis vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acellular pertussis vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TQL1055</intervention_name>
    <description>Semisynthetic saponin adjuvant</description>
    <arm_group_label>TQL1055</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Acellular pertussis vaccine</intervention_name>
    <description>Acellular pertussis vaccine</description>
    <arm_group_label>Acellular pertussis vaccine</arm_group_label>
    <arm_group_label>TQL1055</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  18 to 50 years of age&#xD;
&#xD;
          -  General good health&#xD;
&#xD;
          -  BMI between 17 and 35 kg/m2&#xD;
&#xD;
          -  Not of childbearing potential OR using adequate contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Prior medical condition that could adversely affect subject safety&#xD;
&#xD;
          -  Clinically significant abnormal laboratory parameter&#xD;
&#xD;
          -  Current acute febrile illness&#xD;
&#xD;
          -  Contraindication to intramuscular injection&#xD;
&#xD;
          -  Contraindication to pertussis vaccination&#xD;
&#xD;
          -  Received pertussis vaccine within 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean R Bennett, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Adjuvance Technologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

